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Membrane transporters of steroid hormones
The discovery of a plasma membrane ABC protein that exports steroids in
yeast highlights the possibility that similar membrane sorting systems in
mammalian cells may modulate the access of steroids to their receptors.
The discovery of intracellular receptors for steroid hor-
mones provided a powerful model that has driven thought
and experimentation in its area of modern biology for
the last 25-30 years. The basic principle of steroid recep-
tors' function is that they are ligand-activated transcrip-
tion factors which bind to specific DNA regulatory sites
and to certain other transcription factors, thereby modu-
lating the transcription of specific gene sets. Steroid hor-
mones are generally thought to diffuse into cells and there
encounter, bind to, and activate, their receptors which
are already in the nucleus or enter it on activation.
During the 1970s and '80s, as steroid binding by the
glucocorticoid receptor was studied in mammalian cell
and tissue systems, many reports documented a correla-
tion between the functional potency of various gluco-
corticoids and their relative binding affinities for the
receptor [1]. These correlations were strong enough that
they could generally be carried over into in vivo applica-
tions, although pharmacokinetic issues also have to be
taken into account in vivo. However, even as the general
concept was developed that glucocorticoids' potency
correlated with their binding affinities for the receptor,
exceptions were noted. These were usually seen as quan-
titative discrepancies between binding and functional
potency, unique to one cell or tissue, or varying between
differing cells and tissues [1,2]. No known mechanism
completely explains these discrepancies, which are often
dismissed as being due to trivial methodological causes. It
seems unlikely, however, that all such variations can be set
aside on these grounds.
One early suggestion was that there might be multiple
glucocorticoid receptors with different binding affinities
and different behaviors on activation, providing the
grounds for the differences between binding and potency.
Indeed, mutations in the ligand-binding domains of sev-
eral steroid receptors are known to alter responses to lig-
and, even causing steroids that normally act as antagonists
to become agonists. Thus, each individual steroid-recep-
tor interaction must cause a change in receptor structure
that affects interactions between the receptor and a com-
plex set of transcription factors. Molecular cloning of the
glucocorticoid receptor, however, has shown it to be the
product of a single gene, and although some mutants of
the glucocorticoid and other steroid receptors are known
to occur in natural mammalian populations, there does
not seem to be an array of cell-type-specific receptors in
normal tissues sufficient to explain the frequent discrep-
ancies between the potency and binding of particular
steroid hormones. Similarly, the known post-translational
modifications of the glucocorticoid receptor have been
unable to account for the data.
Another suggested explanation for the discrepancy
between binding and potency invokes modulatory DNA
motifs. A regulatory DNA sequence named GME (gluco-
corticoid modulatory element), which confers enhanced
responsiveness to glucocorticoids without itself binding
receptor (which has specific binding motifs elsewhere in
the promoter) has been identified in the promoter of the
tyrosine aminotransferase gene [3]. When present, this
control sequence shifts the dose-response curve for gluco-
corticoid induction of the gene to the left, increasing the
apparent potency of several glucocorticoids. The GME
sequence can even cause the anti-glucocorticoid dexa-
methasone mesylate to become an agonist [3]. One inter-
pretation of these results is that interactions between the
glucocorticoid receptor-ligand complex and other tran-
scription factors are affected by the presence of the GME,
which may have its own unique binding proteins. If such
interactions can change the function of a ligand antagonist
to that of an agonist, then it is possible that the pattern
of relative potencies of other ligands could shift as well,
depending on subtle modulations in receptor structure
and protein-protein interactions. The distribution of the
GME sequence in the genome is unknown; nor do we
have a detailed knowledge of proteins that bind to it.
Yet another way that cells might alter the effectiveness of
specific steroids is by controlling access of steroids to their
receptors. For example, metabolic processes are some-
times used to convert inactive steroids to active forms,
and vice versa. An example of the former is the conversion
of cortisone, which has little or no binding activity, to
cortisol, by conversion of the 11-one to 11-ol. A well
known example of steroid inactivation is removal of the
11 -hydroxyl group of cortisol and other glucocorticoids
by 113p-hydroxysteroid dehydrogenase in the kidney;
occupancy and inappropriate activation of the mineralo-
corticoid receptor by glucocorticoids is thus prevented,
leaving the way free for the action of aldosterone, which
circulates at lower concentrations than glucocorticoids.
The cell's plasma membrane is a natural filtering and
sorting device for many compounds, and it may be used
to sort steroids, too. In the laboratory practice of using
non-mammalian eukaryotes to study steroid actions, this
can be an annoyance. Recently, several labs have carried
out studies of steroid receptor function in yeast. The
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Fig. 1. How the yeast plasma membrane
ABC transporter LEM1 alters the bio-
logical potency of glucocorticoids from
that predicted by their binding affinities
for the glucocorticoid receptor. Three
glucocorticoids (G1, G2 and G3) are
shown, with affinities for binding to
the receptor in descending order,
G3>G2>G1. When applied to yeast
cells, however, their effective potencies
are changed as a result of the action of
LEM1, which exports much of G2 and
G3 but allows free entry of G1.
powerful genetic manipulations that can be performed
in these simple organisms makes them very attractive for
analysis of expressed mammalian genes. Furthermore,
yeast lack glucocorticoid receptors, providing a 'zero
background' against which to study the actions of expres-
sed receptors. However, several popular, potent synthetic
glucocorticoids, used widely to activate their receptors in
mammalian systems, have proven to be only weak ago-
nists in yeast. On the other hand, the relatively weak
agonist deoxycorticosterone functions well in yeast cells.
Kralli et al. [4] have made a virtue of this problem in
recently published work. Correctly suspecting that there
was a membrane barrier involved in the failure of gluco-
corticoid receptors expressed in yeast cells to respond to
low concentrations of some agonists, they used the power
of yeast genetics to identify a mutation that allowed acti-
vation of the glucocorticoid receptor by concentrations
of triamcinolone and dexamethasone far below those
usually required, while not affecting the deoxycortico-
sterone dose-response curve. By complementation analy-
sis, the gene responsible for this effect was obtained and
its protein product identified. The wild-type protein,
named LEM1 by the authors, was found to be a member
of the ABC (ATP-binding cassette) superfamily of trans-
porter proteins. Members of this family have a structure
in which two ATP-binding domains alternate with two
hydrophobic motifs, each of which spans the membrane
six times. They have ATPase and chloride channel activ-
ity and function to transport a variety of compounds of
more or less hydrophobic character; they have been the
subject of several recent reviews [5,6].
LEM1 selectively pumps dexamethasone and triamcino-
lone, but not deoxycorticosterone, from yeast cells.
Thus its inactivation in the mutant allows the synthetic
ligands to enter freely, activating the glucocorticoid
receptor according to their binding affinities (see Fig. 1).
Interestingly, based on entirely different selection criteria,
the LEM1 gene was independently cloned and identified
as encoding an ABC transporter protein by two other
groups - in one case as PDR5, cloned for resistance to
cycloheximide [7], and in the other as STS1, conferring
resistance to sporidesmin [8]. If this sort of behavior - a
single membrane protein providing resistance to several
unrelated compounds - sounds familiar, it should. A
widely studied member of the ABC superfamily in mam-
malian cells is the P glycoprotein product of the multiple
drug resistance (MDR1) gene [6]. This protein confers
resistance to a number of structurally dissimilar com-
pounds. It is often expressed at high levels in cancer cells,
but is also found in some normal tissues, particularly in
the membranes of steroid-secreting cells and cells of
transporting epithelia. The P glycoprotein can bind sev-
eral steroids and can export some of them [6,9-12]; it has
been speculated that its naturally high expression in the
adrenal gland permits adrenal cells to handle their high-
steroid environment. Years ago, selection for mouse lym-
phomas produced a 'membrane mutant' which excluded
glucocorticoids, and this effect turned out to be due to
high expression of MDR 1 [9].
Kralli et al. [4] suggest that membrane sorting of steroids
in mammalian cells may be more widespread than we
think. ABC proteins are found across vast taxonomic
and phylogenetic spreads, from the ascomycete yeasts in
the Kingdom Fungi, to the Animal Kingdom, where
they have been widely studied in two disparate phyla -
insects and vertebrates. Nature has a way of using the
same structural motifs in proteins for differing functions
across phylogenetic distances. This could mean that the
functions of LEM1 may be special for yeast. Nature also
has a way, however, of preserving vital functions lodged
in particular proteins. Whether the steroid barrier that
LEM1 provides for yeast will prove to be reflected as an
analogous major natural function for the P glycoprotein
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and other yet-to-be-found members of the ABC group
of proteins in mammals remains to be seen. At present
we can only speculate about the natural functions of
both LEM1 and P glycoprotein. Perhaps subtle sorting
of steroids will prove to be one duty of proteins of the
ABC family.
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